Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

1.3K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
1.3K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

1.1K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.1K
Obesity01:24

Obesity

1.5K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

1.1K
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
1.1K
Drugs Acting on Autonomic Ganglia: Blockers01:28

Drugs Acting on Autonomic Ganglia: Blockers

1.8K
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.8K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

2-Pentadecyl-2-oxazoline alleviates anxiety-like behaviour and modulates the microbiota-gut-brain axis in obese mice.

Frontiers in pharmacology·2026
Same author

F2F-202, a Selective Histone Deacetylase 6 (HDAC6) Inhibitor, Behaves as an Arrow with Multiple Tips against Azole-Resistant <i>C. albicans</i>: Modulation of Yeast-to-Hyphae Transition, Trailing Effect, and Oxidative Stress.

ACS infectious diseases·2026
Same author

Editorial: Innovative therapeutic strategies targeting early-life gut microbiota: pathways to long-term health benefits.

Frontiers in microbiology·2025
Same author

Autism spectrum disorders and nutritional interventions: dimethylglycine and B-vitamins effects on behaviour, inflammation, microbiota and mitochondria in liver and brain synapses.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2025
Same author

Skin Microbiome Overview: How Physical Activity Influences Bacteria.

Microorganisms·2025
Same author

Effect of elite sport activity on salivary microbiota: The case of water polo.

Heliyon·2024

Related Experiment Video

Updated: Mar 14, 2026

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

25.3K

Botulinum Toxin A for Controlling Obesity.

Raffaela Pero1, Lorena Coretti2, Francesca Lembo3

  • 1Department of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", Naples 80131, Italy. pero@unina.it.

Toxins
|September 30, 2016
PubMed
Summary

Botulinum toxin type A (BoNT-A) shows promise for obesity treatment, but results are debated. Further research is needed to standardize its use for effective weight management.

Keywords:
botulinum toxin Aintragastric injectionobesity

More Related Videos

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.8K
Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

16.6K

Related Experiment Videos

Last Updated: Mar 14, 2026

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

25.3K
An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.8K
Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

16.6K

Area of Science:

  • Gastroenterology
  • Endocrinology
  • Pharmacology

Background:

  • The global rise in obesity necessitates novel therapeutic strategies beyond diet, exercise, and traditional pharmacology.
  • Obesity results from an energy imbalance, with caloric intake exceeding energy expenditure.

Approach:

  • This review examines the current scientific understanding and clinical evidence of Botulinum toxin type A (BoNT-A) for obesity treatment.
  • It analyzes studies investigating BoNT-A's effects on gastric function and food intake in both animal models and human trials.

Key Points:

  • Botulinum toxin type A (BoNT-A) is being explored for various medical conditions, including obesity.
  • Studies on BoNT-A's efficacy in treating obesity via gastric injections have yielded mixed results.
  • Variations in patient selection, dosage, administration methods, and outcome measurements contribute to the debated outcomes.

Conclusions:

  • While basic science models suggest BoNT-A can reduce food intake and body weight, clinical evidence for obesity treatment remains inconclusive.
  • Standardization of treatment protocols is crucial for future research and potential therapeutic application of BoNT-A in obesity management.